About 100 reports

  • SJÖGREN'S SYNDROME

PLoS One, ##(##), e##.

  • Lymphoma
  • European Union
  • Japan
  • United States
  • Roche Group

The study identified novel HIV-## CAIs with highly potent antiviral activity and a favorable resistance profile to existing ARVs in vitro.

  • HIV AIDS
  • Lymphoma
  • Pharmaceutical
  • United States
  • Gilead Sciences, Inc.

This JAK/ STAT activation mediates signal transduction and activates various immunomodulatory and antiviral proteins.

  • Blood Disease
  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • SD-101 - DRUG PROFILE

GIVEN THAT THE ACTIVATION OF OTHER TLRS CAN INDUCE TYPE I IFN PRODUCTION, LIGANDS OF TLR-## IS CAPABLE OF INDUCING ANTIVIRAL ACTIVITY AGAINST HCV IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS).

  • Cancer
  • Leukemia
  • Lymphoma
  • United States
  • Product Initiative

Tissue inhibitor of metalloproteinase ## (TIMP-##) showed statistically significant reduction; mean change of TIMP-##, -##. ## IU, P=##. ##.

  • Hospital
  • Immunotherapy
  • Lymphoma
  • Therapy
  • TaiwanJ Pharmaceuticals Co., Ltd.

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Immunotherapy
  • Lymphoma
  • United States
  • Product Initiative
  • Idera Pharmaceuticals, Inc.

Exportin ## (Chromosome Region Maintenance ## Protein Homolog or XPO##) - Overview Exportin ## (XPO##) or chromosomal maintenance ## (CRM##) is a eukaryotic protein.

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Karyopharm Therapeutics Inc.

Both were monodermatomal and resolved with antiviral therapy.

  • Lymphoma
  • Research And Development
  • United States
  • Product Initiative
  • Pfizer Inc.
  • Official Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • HIV AIDS
  • Lymphoma
  • Medical Biotechnology
  • World
  • Product Initiative

It provides antiviral, Parkinson' s drug, HIV drug, and anticancer drugs.

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Epizyme, Inc.

This JAK/ STAT activation mediates signal transduction and activates various immunomodulatory and antiviral proteins.

  • Lung Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Incyte Corporation
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • HIV AIDS
  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • F. Hoffmann-La Roche Ltd.

DEAL IN BRIEF PARTNER ##: AMGEN, INC.

  • Hospital
  • Lymphoma
  • Company
  • Corporate Finance
  • Arrowhead Research Corporation
  • Official Title

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Infectious Disease
  • Lymphoma
  • Therapy
  • GlaxoSmithKline plc

Twenty-one patients (##%) were refractory to prior treatment.

  • Lymphoma
  • Therapy
  • Company
  • Company Operations
  • TG Therapeutics, Inc.

Partner ## Partner ## Partner ## Cleveland BioLabs, Inc.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Corporate Finance
  • Abviva, Inc.
  • SD-101 - DRUG PROFILE

The biomarker data point to substantial, dose-related increases in the expression of key antiviral genes (MX-B and ISG-##k) and genes indicating enhanced immunity (IP-## and MCP-##).

  • Leukemia
  • Lymphoma
  • Oncology
  • Therapy
  • Celgene Corporation

Each unit consists of one share and a warrant to purchase one half of a share of its common stock.

  • Lymphoma
  • Therapy
  • United States
  • Company
  • Ogden Golf Co.

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Lymphoma
  • World
  • Product Initiative
  • PIPELINE BY KAINOS MEDICINE INC, H2 2017

It provides antiviral, Parkinson' s drug, HIV drug, and anticancer drugs.

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Epizyme, Inc.
  • SMALL MOLECULES TO INHIBIT EBNA1 FOR EPSTEIN-BARR VIRUS INFECTIONS - DRUG PROFILE
  • VRX-3996 - DRUG PROFILE

The company also has discovery antiviral programs.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Bristol-Myers Squibb Company

DEAL IN BRIEF PARTNER ##: AMGEN, INC.

  • Hospital
  • Lymphoma
  • Company
  • Corporate Finance
  • Arrowhead Research Corporation

It offers products in the therapeutic areas of oncology, hematology, immune diseases, antibiotics, antivirals, neurology, cardiology, multiple sclerosis, hemophilia and diabetes, among others.

  • Endocrine Disease
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Alnylam Pharmaceuticals, Inc.
  • PIPELINE BY HUTCHISON MEDIPHARMA LTD, H1 2018

The company' s products serve in fields of medicinal chemistry, pharmacology, oncology, cardiovascular and respiratory diseases, and antiviral treatments.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

The drug candidates are developed based on Nested Chemical Library (NCL) technology and antiViral-hyperActivation limiting therapeutics.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Exportin ## (Chromosome Region Maintenance ## Protein Homolog or XPO##) - Overview EXPORTIN ## (XPO##) OR CHROMOSOMAL MAINTENANCE ## (CRM##) IS A EUKARYOTIC PROTEIN.

  • Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Karyopharm Therapeutics Inc.
  • 5. All the trials included are unique trials.

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Takeda Pharmaceutical Co Ltd ## ## ## ## ## ## ## ## Celgene Corp ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## Amgen Inc ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## Jo

  • Cancer
  • Lymphoma
  • United States
  • World
  • Product Initiative

Partner ## Partner ## Partner ## Cleveland BioLabs, Inc.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Corporate Finance
  • Abviva, Inc.

Partner ## Partner ## Partner ## Deal status Deal category Deal sub-category Date of announcement COMPANY INFORMATION: PARTNERS Company type PARTNER ##: SHENZHEN MAIN LUCK PHARMACEUTICALS INC Private ORChem Co., Ltd.

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Company
  • Celltrion, Inc.

THE POTENTIAL VALUE OF THIS DRUG AS SINGLE THERAPY OR IN COMBINATION WITH ANTIVIRALS IS FURTHER SUPPORTED BY PREVIOUS RESEARCH THAT FOUND THAT IT IS SAFE FOR USE IN HUMANS.

  • Hospital
  • Lymphoma
  • United States
  • World
  • Product Initiative